What is HC Wainwright’s Estimate for JSPR FY2029 Earnings?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Research analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Jasper Therapeutics in a note issued to investors on Wednesday, January 8th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($10.81) per share for the year. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

A number of other analysts have also weighed in on the stock. Royal Bank of Canada reduced their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research note on Thursday. JMP Securities reissued a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a research note on Monday, January 6th. Finally, BMO Capital Markets began coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $63.00 target price for the company. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics currently has a consensus rating of “Buy” and an average price target of $67.75.

Jasper Therapeutics Trading Up 0.9 %

Shares of NASDAQ:JSPR opened at $7.05 on Friday. The company has a 50 day moving average of $21.09 and a 200-day moving average of $20.16. The firm has a market cap of $105.76 million, a P/E ratio of -1.49 and a beta of 2.18. Jasper Therapeutics has a twelve month low of $6.57 and a twelve month high of $31.01.

Institutional Investors Weigh In On Jasper Therapeutics

A number of large investors have recently made changes to their positions in JSPR. JPMorgan Chase & Co. increased its stake in Jasper Therapeutics by 239.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock valued at $308,000 after buying an additional 11,567 shares during the period. Barclays PLC increased its stake in Jasper Therapeutics by 320.7% in the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock valued at $304,000 after buying an additional 12,308 shares during the period. Jane Street Group LLC acquired a new position in Jasper Therapeutics in the 3rd quarter valued at approximately $251,000. Wellington Management Group LLP acquired a new position in Jasper Therapeutics in the 3rd quarter valued at approximately $447,000. Finally, State Street Corp grew its position in Jasper Therapeutics by 12.3% in the third quarter. State Street Corp now owns 214,883 shares of the company’s stock worth $4,042,000 after acquiring an additional 23,564 shares in the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.